TECX Stock Analysis: Buy, Sell, or Hold?
TECX - Tectonic Therapeutic, Inc. Common Stock
$29.10
-0.25 (-0.85%)
▼
5d:
-1.15%
30d:
+24.09%
90d:
+39.37%
BUY
HIGH Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When TECX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TECX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TECX shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: TECX is currently trading at $29.10, which is considered fair relative to its 30-day fair value range of $23.95 to $33.19.
Technical Outlook: Technically, TECX is in a strong uptrend. Immediate support is located at $28.20, while resistance sits at $34.46.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.25 (+166.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TECX is in a strong uptrend. Immediate support is located at $28.20, while resistance sits at $34.46.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $78.25 (+166.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$23.95 -
$33.19
Company Quality Score
57/100
(HOLD)
Options IV Signal
18th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 18th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 166.6% below Wall St target ($78.25)
Fair Price Analysis
30-Day Fair Range
$23.95 -
$33.19
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$5.48
(18.8%)
Support & Resistance Levels
Support Level
$28.20
Resistance Level
$34.46
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.53
Wall Street Target
$78.25
(+166.6%)
Share & Embed Analysis
Last updated: March 30, 2026 10:27 AM ET
Data refreshes hourly during market hours. Next update: 11:27 AM
Data refreshes hourly during market hours. Next update: 11:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TECX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Marcella K Ruddy
SELL
10000 shares
2026-03-06
Peter Mcnamara
SELL
6262 shares
2026-03-06
Peter Mcnamara
SELL
1650 shares
2026-03-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 56 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 56 HOLD |
